Anastrol 1 1mg
Anastrozole
Category: Tablet
Manufacturer: Beacon Pharmaceuticals Ltd.
Price: 50.0 ৳
Tablet
Strip
Box
Related Medicines
Anastrol 1 is indicated in-
Treatment of early breast cancer in hormone receptor positive post-menopausal women.
Adjuvant treatment of early breast cancer in hormone receptor positive
postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Reduction in the incidence of contralateral breast cancers in post menopausal women receiving Anastrol 1 as adjuvant treatment for early breast cancer.
Treatment of advanced breast cancer in post-menopausal women.
Hormonal Chemotherapy
The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
Adults and elderly: 1 mg tablet to be taken orally once a day.
Tamoxifen and/or other therapies containing estrogen should not be co-administered with Anastrozole.
Patients with severe renal impairment (Creatinine clearance less than 20 mL/min), patients with moderate to severe hepatic disease and known hypersensitivity to anastrozole or to any of the excipients. Oestrozen-containing therapies should not be co-administered with anastrazole as they would negate its pharmacological action.
Very common side effects: Hot flushes, asthenia, joint stiffness, arthritis, headache, nausea, rash etc. Common side effects: Hair thinning, allergic reactions, diarrhea, vomiting, somnolence etc.
Anastrozole is contraindicated in pregnant and lactating women.
Anastrozole is not recommended for use in children or in pre-menopausal women as safety and efficacy have not been established in these groups of patients.
Anastrozole has not been investigated in patients with severe hepatic or severe renal impairment. The potential risk/benefit to such patients should be carefully considered before administration of Anastrozole.
As Anastrozole lowers circulating estrogen levels, it may cause a reduction in bone mineral density with a possible consequent increased risk of fracture.
There is limited clinical experience of overdose of Anastrozole. There are no reports where a patient has taken a dose in excess of 60 mg. No toxicity was observed and no clinically relevant adverse effects have been seen.
Store in a cool & dry place, protected from light and moisture. Keep out of reach of children.
Hormonal Chemotherapy
Anastrazole exerts its anti-estrogenic effects via selective and competitive inhibition of the aromatase enzyme found predominantly in the adrenal glands, liver, and fatty tissues. Many breast cancers are hormone receptor-positive, meaning their growth is stimulated and/or maintained by the presence of hormones such as estrogen or progesterone. In postmenopausal women, estrogen is primarily derived from the conversion of adrenally-produced androgens into estrogens by the aromatase enzyme- by competitively inhibiting the biosynthesis of estrogen at these enzymes, anastrozole effectively suppresses circulating estrogen levels and, subsequently, the growth of hormone receptor-positive tumours.
Anastrozole must not be administered during pregnancy or lactation.
Login
Please log in to start communication with AI.